EZACARD

EZACARD  75

EZACARD 75
COMPOSITION: Each enteric-coated tablet contains: Acetyl salicylic acid (Aspirin) 75 mg.
PROPERTIES:
Aspirin is a potent inhibitor of both prostaglandin synthesis and platelet aggregation. By decreasing platelet
aggregation aspirin (Ezacard) will inhibit formation on the arterial side of the circulation where thrombi are formed by
platelet aggregation and anticoagulants have little effect. Ezacard is useful for the secondary prevention of thrombotic
cerebrovascular or cardiovascular disease. It is used to reduce mortality after myocardial infarction and also given
following bypass surgery.
Being enteric-coated, Ezacard tablets will not disintegrate or release aspirin in the stomach so gastric irritation side
effects usually induced by aspirin are eliminated.
INDICATIONS:
• Vascular indications: (Ischemic stroke, TIA, Acute Ml, prevention of recurrent Ml, unstable angina pectoris,
and chronic stable angina pectoris).
- Reduce the combined risk of death and non-fatal stroke in patients who have had ischemic stroke of transient
ischemia of the brain due to fibrin platelet emboli.
- Reduce the risk of vascular mortality in patients with chronic stables angina pectoris.
• Following Revascularization procedures: (Coronary Artery Bypass Graft, Percutaneous Transluminal
Coronary Angioplasty and Carotid Endarterectomy), where there is a pre-existing condition for which aspirin is
already indicated.
WARNINGS AND PRECAUTIONS:
Gastrointestinal Risk: NSAlDs cause an increased risk of serious gastrointestinai adverse events including
inflammation, bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can
occur at anytime during use and without warring symptoms. Elderly patients are at greater risk for serious
gastrointestinal events.
Precaution should be exercised in cases of asthma; uncontrolled hypertension; pregnancy (impaired platelet function
and risk of haemorrhage; delayed onset and increased duration of labour with increased blood loss); avoid in last 3
months of pregnancy; with high doses, closure of fetal ducts arteriosus in utero and possibly persistent pulmonary
hypertension and blood coagulation in newborn; kernicterus in jaundiced neonates.
DRUG INTERACTIONS:
• Increased risk of bleeding (due to antiplatelet effect) with anticoagulants.
• Avoid concomitant administration of other NSAlDs (increased side effects).
• Antiacids and adsorbents: Excretion increased in alkaline urine. Kaolin reduces absorption.
• Effect of phenytoin and valproate is enhanced.
• Increased risk of bleeding with other antiplatelet drugs.
• Corticosteroids: Increased risk of gastro-intestinal bleeding and ulceration; corticosteroids reduce plasmasalicylate concentration.
• Cytotoxics: Reduced excretion of methotrexate (increased toxicity).
• Antagonism of diuretic effect of spironolactone; reduced excretion of acetazolamide (Risk of toxicity).
• Leukotriene antagonists: Aspirin increases plasma concentration of zafirlukast.
• Metoclopramide enhances effect of aspirin (increased rate of absorption).
• Avoid aspirin until 8 — 12 days after mifepriston.
• Effect of probenecid and sulfinpyrazone is reduced.
CONTRAINDICATIONS:
• Hypersensitivity to NSAlDs.
• Peptic ulceration.
SIDE EFFECTS:
• Childr;n under 12 years.
• Breast feeding.
• Haemophilia and other bleeding disorders.
Being enteric-coated Ezacard tablets do not cause stomach irritation which is usually induced by aspirin. However,
other side effects include bronchospasm; gastro-intestinal haemorrhage (occasionally major), also other
haemorrhage (e.g.Subconjunctival).
DOSAGE AND ADMINISTRATION:
The whole tablet is swallowed and should never be crushed or chewed.
- Secondary prevention of thrombotic cerebrovascular or cardiovascular disease: 75-300mg daily.
- Angina: 75-150 mg daily.
STORAGE: Store in a cool dry below 300 C.
PACKAGING: Each box contains 3 strips each of 10 tablets.
Keep All Medicine Out of Reach of Children
Manufactured by Multi-Apex for Pharmaceutical Industries - S.A.E. - Badr City - Egypt.